A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H1 2017

  • ID: 4311854
  • Report
  • 45 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Asahi Kasei Pharma Corp
  • Galapagos NV
  • GlaxoSmithKline Plc
  • Rottapharm Biotech Srl
  • MORE
A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H1 2017

Summary:

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - A disintegrin and metalloproteinase with thrombospondin motifs 5 or ADAMTS5 is an enzyme encoded by the ADAMTS5 gene. It plays an important role in the destruction of aggrecan in arthritic diseases and in proteolytic processing mostly during the peri-implantation period.

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1 and 1 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular and Respiratory which include indications Osteoarthritis, Allergic Asthma, Arthralgia, Arthritis, Edema and Seasonal Allergic Rhinitis.

The latest report A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H1 2017, outlays comprehensive information on the A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.)
  • The report reviews A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Asahi Kasei Pharma Corp
  • Galapagos NV
  • GlaxoSmithKline Plc
  • Rottapharm Biotech Srl
  • MORE
  1. Introduction
  2. A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Overview
  3. A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Therapeutics Assessment
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Companies Involved in Therapeutics Development
  13. Asahi Kasei Pharma Corp
  14. Galapagos NV
  15. GlaxoSmithKline Plc
  16. Paradigm Biopharmaceuticals Ltd
  17. Rottapharm Biotech Srl
  18. A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Drug Profiles
  19. CRB-0017 - Drug Profile
  20. Product Description
  21. Mechanism Of Action
  22. R&D Progress
  23. GLPG-1972 - Drug Profile
  24. Product Description
  25. Mechanism Of Action
  26. R&D Progress
  27. GSK-2394002 - Drug Profile
  28. Product Description
  29. Mechanism Of Action
  30. R&D Progress
  31. pentosan polysulfate sodium - Drug Profile
  32. Product Description
  33. Mechanism Of Action
  34. R&D Progress
  35. Small Molecules to Inhibit ADAMTS-5 for Osteoarthritis - Drug Profile
  36. Product Description
  37. Mechanism Of Action
  38. R&D Progress
  39. A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Dormant Products
  40. A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Product Development Milestones
  41. Featured News & Press Releases
  42. May 16, 2017: Paradigm’s preclinical hay fever trial: peer-reviewed and published in leading scientific journal
  43. Apr 29, 2017: Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI
  44. Mar 23, 2017: Paradigm Biopharmaceuticals Announces Final participant treated in Phase 2 hay fever trial
  45. Mar 07, 2017: The Australian Company Testing a Breakthrough Treatment for Ross River
  46. Nov 22, 2016: Paradigm Phase 2 Hay Fever Trialgets Approval from Swedish MPA
  47. Sep 16, 2016: Preclinical study underpins efficacy of Paradigms Rhinosul for hay fever treatment
  48. Sep 07, 2016: Paradigm’s PPS as a potential breakthrough in t he treatment of viral arthritis and joint pain
  49. Aug 19, 2016: Market update Paradigm’s PPS nasal spray to treat Allergic Rhinitis (Hay Fever)
  50. May 25, 2016: Paradigm Biopharmaceuticals Provides Update on Rhinosul (pentosan polysulfate sodium)
  51. Mar 02, 2016: Paradigm initiates second clinical trial site to investigate ZILOSUL as a treatment for bone bruising following Anterior Cruciate Ligament (ACL) injury
  52. Feb 25, 2016: First participant in Paradigm’s clinical trial starts ZILOSUL treatment for bone bruising following Anterior Cruciate Ligament (ACL) injury
  53. Feb 23, 2016: Paradigm starts clinical trial to investigate ZILOSUL as a treatment for bone bruising following Anterior Cruciate Ligament (ACL) injury
  54. Dec 03, 2015: Elite athlete from a major sporting code treated with Paradigm’s ZILOSUL under the Therapeutic Goods Administration’s Special Access Scheme
  55. Nov 23, 2015: Paradigm’s ZILOSUL approved for clinical trial
  56. Nov 20, 2015: Galapagos initiates Phase 1 First-in-Human study with GLPG1972, receives EU3.5 million milestone from Servier
  57. Appendix
  58. Methodology
  59. Coverage
  60. Secondary Research
  61. Primary Research
  62. Expert Panel Validation
  63. Contact Us
  64. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indication, H1
  4. Number of Products under Development by Companies, H1
  5. Products under Development by Companies, H1
  6. Number of Products by Stage and Mechanism of Actions, H1
  7. Number of Products by Stage and Route of Administration, H1
  8. Number of Products by Stage and Molecule Type, H1
  9. Pipeline by Asahi Kasei Pharma Corp, H1
  10. Pipeline by Galapagos NV, H1
  11. Pipeline by GlaxoSmithKline Plc, H1
  12. Pipeline by Paradigm Biopharmaceuticals Ltd, H1
  13. Pipeline by Rottapharm Biotech Srl, H1
  14. Dormant Projects, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products by Stage and Mechanism of Actions, H1
  5. Number of Products by Routes of Administration, H1
  6. Number of Products by Stage and Routes of Administration, H1
  7. Number of Products by Molecule Types, H1
  8. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Asahi Kasei Pharma Corp
  • Galapagos NV
  • GlaxoSmithKline Plc
  • Paradigm Biopharmaceuticals Ltd
  • Rottapharm Biotech Srl
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll